Press Release Details

Cerus and Bonfils Blood Center Enter Into Agreement for the Use of INTERCEPT Platelets and Plasma

July, 13 2015

CONCORD, Calif. & DENVER--(BUSINESS WIRE)-- Cerus Corporation (NASDAQ:CERS) announced today that Bonfils Blood Center has signed a three-year purchase agreement for the INTERCEPT Blood System for platelets and plasma. Bonfils provides blood and blood products to more than 100 hospitals and healthcare facilities across Colorado and beyond, supplying approximately 20,000 platelet and 25,000 plasma units per year. Bonfils is an affiliate of Blood Systems Inc., one of the largest blood product and service providers in the U.S.

This Smart News Release features multimedia. View the full release here:

“We are excited to partner with Cerus to make INTERCEPT pathogen reduction another important option for our healthcare clients as we work in collaboration to deliver on our mission to ‘save and enhance lives through transfusion medicine excellence,’” said Bryan Krueger, Bonfils Blood Center President and Chief Executive Officer.

“We are pleased to offer the use of INTERCEPT pathogen reduction to enhance the quality of care provided at the hospitals we serve and for the patients for which they provide treatment,” said Tuan Le, MD, Medical Director and Vice President of Medical Affairs at Bonfils Blood Center.

"Bonfils has been a valuable research partner for us, contributing significantly to studies we've used to support our current FDA approvals and also future product extensions," commented William "Obi" Greenman, Cerus’ President and Chief Executive Officer. "We are pleased to expand this relationship and now become their pathogen reduction supplier."


For more than 70 years, Bonfils Blood Center has held a presence in this community as one of Colorado’s top nonprofit healthcare organizations. Bonfils is proud to have become a trusted community resource and source of hope for those in their time of need as well as an outlet for its neighbors wanting to give back through blood, marrow and financial donations. In order to meet the needs of more than 100 healthcare facilities Bonfils serves and to be prepared for unexpected events, Bonfils must collect more than 3,000 blood donations each week. For information about Bonfils Blood Center please call 303.366.2000 or visit or look for Bonfils on Facebook, Twitter and Instagram.


Cerus Corporation is a biomedical products company focused in the field of blood safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as Hepatitis B and C, HIV, West Nile Virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See for information about Cerus.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

Source: Cerus Corporation

Cerus Corporation

Lainie Corten, 925-288-6319

Vice President, Global Marketing & Investor Relations


Bonfils Blood Center

Jessica Maitland, 303-517-0318

Vice President, Marketing and Community Development

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600